Colitis Organization News Today

A radioactive tracer developed by Astra Zeneca and the Karolinska Institutet may play a major role for patients with Crohns disease. That is the belief of Maria Belvisi at AstraZeneca.

Biosimilar approved; clinical trial data supports early intensive therapy

Vedolizumab had greater treatment persistence than tofacitinib in a retrospective study of patients with ulcerative colitis (UC) who were previously bio-naive.

Long-term data show clinical remission and endoscopic response rates are maintained and even improve over time in patients with moderate to severe Crohn's disease, according to a new study.

EQS-News: ABIVAX / Key word: Conference Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th...

EQS-News: ABIVAX / Key word(s): ConferenceAbivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO) 13.02.2024 / 08:30 CET/CESTThe issuer is solely responsible for the content o...

Bruce Sands, MD, MS.,Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenter...

Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology,...

/PRNewswire/ -- The "Ulcerative Colitis (UC) - Epidemiology Forecast to 2032" report has been added to ResearchAndMarkets.coms offering. This comprehensive...

Subcutaneous infliximab achieved greater clinical remission and endoscopic response rates compared with placebo in patients with inflammatory bowel disease and has potential to become a more convenient, “patient-centric” treatment option.“Infliximab has been used in clinical practice for more than 20 years, and it is known to be one of the most effective IBD treatments,”